
    
      Prospective, two arms, randomized multi-center trial of 1,056 patients enrolled at 3 centers
      in Korea.

      Following angiography, patients with significant diameter stenosis >50% by visual estimation
      have documented myocardial ischemia or symptoms of angina and eligible for stenting without
      any exclusion criteria will be randomized 1:1 to: a) Pregrel® group vs. b) Plavix®. This
      trial is the non-inferiority study to demonstrate that the incidence of 12 months primary
      end-point in Pregrel® group.
    
  